Fundacion Respirar | Clinical Independency Research

Research site

(Unclaimed)

Location

Luis Maria Drago 5681, Buenos Aires, Buenos Aires, Argentina

Site insights

Top conditions

Top treatments

BMS-986278

Tarlatamab

Baricitinib

Bemarituzumab

LY3009104

Gedatolisib

Nivolumab

AP01

Povorcitinib

Parent organization

This site is a part of Fundacion Respirar

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 8 total trials

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus pla...

Enrolling

Progressive Pulmonary Fibrosis

Drug: AP01

Other: Placebo

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma

The study is being conducted to evaluate the effect of 3 dosing regimens of povorcitinib on pulmonary function

Enrolling

Moderate to Severe Asthma

Drug: ICS-LABA

Other: placebo

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Enrolling

Idiopathic Pulmonary Fibrosis

Drug: BMS-986278

Drug: BMS-986278 Placebo

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Enrolling

Progressive Pulmonary Fibrosis

Drug: BMS-986278 Placebo

Drug: BMS-986278

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (FORTITUDE-102)

The main objective of Part 1 is to evaluate the safety and tolerability of bemarituzumab plus 5-fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6)...

Active, not recruiting

Gastric Cancer

Gastroesophageal Junction Adenocarcinoma

Other: Placebo

Drug: Nivolumab

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant and CDK4/6 Inhibitors fo...

Enrolling

Breast Cancer

Drug: Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant

Drug: Arm B: Palbociclib or Ribociclib + Fulvestrant